Critical Gaps in Cardiac Screening for Cancer Patients: A Study Analysis

A recent study published in The American Journal of Cardiology highlights significant gaps in cardiac screening and monitoring for cancer patients undergoing cardiotoxic treatments, largely influenced by provider-level factors. This comprehensive analysis utilized the SEER-Medicare database and hospital-level data, concentrating on female Medicare beneficiaries aged 66 and older who received treatments such as immune checkpoint inhibitors (ICIs), anti-HER2 agents, or anthracyclines between 2014 and 2018.

The study revealed that only 37% of the 2,143 patients received baseline cardiac screening, with follow-up cardiac monitoring after treatment initiation administered to fewer than 1%. Specifically, baseline screening rates were 11% for patients on ICIs, 58% for those on anthracyclines, and 54% on anti-HER2 agents. Variability in screening practices was largely attributed to provider-level factors at 12%, compared to a minimal 3% linked to hospital-level factors.

Patient demographics showed that those deemed high-risk were more likely to receive baseline screening, while individuals with a history of alcohol use had reduced screening uptake. The study acknowledged limitations such as incomplete provider-level data, lack of comprehensive comorbidity accounting, and reduced applicability to non-Medicare Advantage or private insurance patients. The authors noted that provider-driven differences greatly influenced cardiac monitoring approaches. For full disclosure details, refer to the original study publication.